Interactions between modafinil and cocaine during the induction of conditioned place preference and locomotor sensitization in mice: Implications for addiction

Behavioural Brain Research

Volumn 235, Issue 2, 2012, Pages 105-112

  Shuman, Tristan ^a   Cai, Denise J ^a   Sage, Jennifer R ^a   Anagnostaras, Stephan G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Activity; Behavior; Dopamine; Provigil; Stimulant

Indexed keywords

COCAINE; MODAFINIL; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR SENSITIZATION; COCAINE DEPENDENCE; CONDITIONING; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SENSITIZATION; FEMALE; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REINFORCEMENT; REWARD; SENSITIZATION;

ANIMALS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM SENSITIZATION; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CONDITIONING, OPERANT; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; MULTIVARIATE ANALYSIS; REWARD; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84865321195     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.07.039     Document Type: Article

References (51)

1. Bastuji H., Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Progress in Neuropsychopharmacology and Biological Psychiatry 1988, 12:695-700.
2. Cephalon FDA Approved Labeling Text for NDA 20-717/S-005 & S008. Provigil® (modafinil) Tablets [C-IV], Approved 23-Jan-2004; 2004.
3. O'Connor A. Wakefulness finds a powerful ally. New York Times 2004.
4. Shuman T., Wood S.C., Anagnostaras S.G. Modafinil and memory: effects of modafinil on Morris water maze learning and Pavlovian fear conditioning. Behavioral Neuroscience 2009, 123:257-266.
5. Beracochea D., Celerier A., Peres M., Pierard C. Enhancement of learning processes following an acute modafinil injection in mice. Pharmacology Biochemistry and Behavior 2003, 76:473-479.
6. Beracochea D., Celerier A., Borde N., Valleau M., Peres M., Pierard C. Improvement of learning processes following chronic systemic administration of modafinil in mice. Pharmacology Biochemistry and Behavior 2002, 73:723-728.
7. Beracochea D., Cagnard B., Celerier A., le Merrer J., Peres M., Pierard C. First evidence of a delay-dependent working memory-enhancing effect of modafinil in mice. Neuroreport 2001, 12:375-378.
8. Turner D.C., Robbins T.W., Clark L., Aron A.R., Dowson J., Sahakian B.J. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 2003, 165:260-269.
9. Garreau J. 'Smart Pills' on the rise. But is taken them wise?. The Washington Post 2006.
10. Ballon J.S., Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. Journal of Clinical Psychiatry 2006, 67:554-566.
11. Karila L., Gorelick D., Weinstein A., Noble F., Benyamina A., Coscas S., et al. New treatments for cocaine dependence: a focused review. International Journal of Neuropsychopharmacology 2008, 11:425-438.
12. Hart C.L., Haney M., Vosburg S.K., Rubin E., Foltin R.W. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008, 33:761-768.
13. Dackis C.A., Kampman K.M., Lynch K.G., Pettinati H.M., O'Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005, 30:205-211.
14. Shearer J. The principles of agonist pharmacotherapy for psychostimulant dependence. Drug and Alcohol Review 2008, 27:301-308.
15. Gold L.H., Balster R.L. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 1996, 126:286-292.
16. Deroche-Gamonet V., Darnaudery M., Bruins-Slot L., Piat F., Le Moal M., Piazza P.V. Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology (Berl) 2002, 161:387-395.
17. Ferraro L., Tanganelli S., O'Connor W.T., Antonelli T., Rambert F., Fuxe K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. European Journal of Pharmacology 1996, 306:33-39.
18. Ferraro L., Antonelli T., O'Connor W.T., Tanganelli S., Rambert F.A., Fuxe K. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biological Psychiatry 1997, 42:1181-1183.
19. Murillo-Rodriguez E., Haro R., Palomero-Rivero M., Millan-Aldaco D., Drucker-Colin R. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behavioural Brain Research 2007, 176:353-357.
20. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. Journal of American Medical Association 2009, 301:1148-1154.
21. Stoops W.W., Lile J.A., Fillmore M.T., Glaser P.E., Rush C.R. Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration. Psychopharmacology (Berl) 2005, 182:186-193.
22. Nguyen T.L., Tian Y.H., You I.J., Lee S.Y., Jang C.G. Modafinil-induced conditioned place preference via dopaminergic system in mice. Synapse 2011, 65:733-741.
23. Wuo-Silva R., Fukushiro D.F., Borcoi A.R., Fernandes H.A., Procopio-Souza R., Hollais A.W., et al. Addictive potential of modafinil and cross-sensitization with cocaine: a pre-clinical study. Addiction Biology 2011, 16:565-579.
24. Paterson N.E., Fedolak A., Olivier B., Hanania T., Ghavami A., Caldarone B. Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacology Biochemistry and Behavior 2010, 95:449-456.
25. Warot D., Corruble E., Payan C., Weil J.S., Puech A.J. Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine, and placebo. European Psychiatry 1993, 8:201-208.
26. Rush C.R., Kelly T.H., Hays L.R., Baker R.W., Wooten A.F. Acute behavioral and physiological effects of modafinil in drug abusers. Behavioural Pharmacology 2002, 13:105-115.
27. Malcolm R., Book S.W., Moak D., DeVane L., Czepowicz V. Clinical applications of modafinil in stimulant abusers: low abuse potential. American Journal of Addiction 2002, 11:247-249.
28. Myrick H., Malcolm R., Taylor B., LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance - a review of abuse liability issues. Annals of Clin Psychiatry 2004, 16:101-109.
29. Minzenberg M.J., Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33:1477-1502.
30. Madras B.K., Xie Z., Lin Z., Jassen A., Panas H., Lynch L., et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. Journal of Pharmacology and Experimental Therapeutics 2006, 319:561-569.
31. Korotkova T.M., Klyuch B.P., Ponomarenko A.A., Lin J.S., Haas H.L., Sergeeva O.A. Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors. Neuropharmacology 2007, 52:626-633.
32. Qu W.M., Huang Z.L., Xu X.H., Matsumoto N., Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. Journal of Neuroscience 2008, 28:8462-8469.
33. Zolkowska D., Jain R., Rothman R.B., Partilla J.S., Roth B.L., Setola V., et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. Journal of Pharmacology and Experimental Therapeutics 2009, 329:738-746.
34. Anagnostaras S.G., Schallert T., Robinson T.E. Memory processes governing amphetamine-induced psychomotor sensitization. Neuropsychopharmacology 2002, 26:703-715.
35. Anagnostaras S.G., Robinson T.E. Sensitization to the psychomotor stimulant effects of amphetamine: modulation by associative learning. Behavioral Neuroscience 1996, 110:1397-1414.
36. Robinson T.E., Berridge K.C. Review. The incentive sensitization theory of addiction: some current issues. Philosophical Transactions of The Royal Society of London Series B-Biological Sciences 2008, 363:3137-3146.
37. Robinson T.E., Berridge K.C. Addiction. Annual Review of Psychology 2003, 54:25-53.
38. Martin-Iverson M.T., Reimer A.R. Classically conditioned motor effects do not occur with cocaine in an unbiased conditioned place preferences procedure. Behavioural Pharmacology 1996, 7:303-314.
39. Schechter M.D., Calcagnetti D.J. Trends in place preference conditioning with a cross-indexed bibliography; 1957-1991. Neuroscience and Biobehavioral Reviews 1993, 17:21-41.
40. Simon P., Hemet C., Costentin J. Analysis of stimulant locomotor effects of modafinil in various strains of mice and rats. Fundamental & Clinical Pharmacology 1996, 10:431-435.
41. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Research: Brain Research Review 1993, 18:247-291.
42. Simon P., Panissaud C., Costentin J. The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice. A comparison with dexamphetamine. Psychopharmacology (Berl) 1994, 114:597-600.
43. van Vliet S.A., Jongsma M.J., Vanwersch R.A., Olivier B., Philippens I.H. Behavioral effects of modafinil in marmoset monkeys. Psychopharmacology (Berl) 2006, 185:433-440.
44. Wood S.C., Fay J., Sage J.R., Anagnostaras S.G. Cocaine, and Pavlovian fear conditioning: dose-effect analysis. Behavioural Brain Research 2007, 176:244-250.
45. Bernardi R.E., Lewis J.R., Lattal K.M., Berger S.P. Modafinil reinstates a cocaine conditioned place preference following extinction in rats. Behavioural Brain Research 2009, 204:250-253.
46. Ackerman J.M., White F.J. A10 somatodendritic dopamine autoreceptor sensitivity following withdrawal from repeated cocaine treatment. Neuroscience Letters 1990, 117:181-187.
47. Pierce R.C., Duffy P., Kalivas P.W. Sensitization to cocaine and dopamine autoreceptor subsensitivity in the nucleus accumbens. Synapse 1995, 20:33-36.
48. De Vries T.J., Schoffelmeer A.N., Binnekade R., Raaso H., Vanderschuren L.J. Relapse to cocaine- and heroin-seeking behavior mediated by dopamine D2 receptors is time-dependent and associated with behavioral sensitization. Neuropsychopharmacology 2002, 26:18-26.
49. Grabowski J., Shearer J., Merrill J., Negus S.S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behaviors 2004, 29:1439-1464.
50. Grabowski J., Rhoades H., Stotts A., Cowan K., Kopecky C., Dougherty A., et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004, 29:969-981.
51. Vosburg S.K., Hart C.L., Haney M., Rubin E., Foltin R.W. Modafinil does not serve as a reinforcer in cocaine abusers. Drug and Alcohol Dependence 2010, 106:233-236.